Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
115 participants
OBSERVATIONAL
2008-11-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol
NCT01119261
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon
NCT01119274
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01119300
Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants
NCT02107651
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
NCT01809015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Signed informed consent
Exclusion Criteria
* Previous or current treatment with any coumarin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jules Desmeules
Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jules A Desmeules, Prof
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Matthey A, Bonnabry P, Dayer P, Desmeules JA. P-glycoprotein: a clue to vitamin K antagonist stabilization. Pharmacogenomics. 2015 Jan;16(2):129-36. doi: 10.2217/pgs.14.164.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER 08-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.